(Q45965493)

18 December 2017

review article

1 reference

title

Why is cancer drug discovery so difficult? (English)

1 reference

18 December 2017

1 reference

Alexander Kamb

1

1 reference

18 December 2017

Susan Wee

series ordinal

2

1 reference

18 December 2017

Christoph Lengauer

series ordinal

3

1 reference

18 December 2017

publication date

8 December 2006

1 reference

18 December 2017

Nature Reviews Drug Discovery

published in

1 reference

18 December 2017

volume

6

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

115-120

1 reference

18 December 2017

Can the pharmaceutical industry reduce attrition rates?

cites work

1 reference

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials

31 March 2020

1 reference

Progress in the development of selective inhibitors of aurora kinases.

31 March 2020

1 reference

Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors

31 March 2020

1 reference

Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

31 March 2020

1 reference

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

31 March 2020

1 reference

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

31 March 2020

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

31 March 2020

1 reference

31 March 2020

1 reference

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

31 March 2020

1 reference

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

31 March 2020

1 reference

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

31 March 2020

1 reference

Strategies to overcome resistance to targeted protein kinase inhibitors

31 March 2020

1 reference

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression

31 March 2020

1 reference

What's wrong with our cancer models?

31 March 2020

1 reference

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

31 March 2020

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

31 March 2020

1 reference

Gastrointestinal stromal tumors (GISTs).

31 March 2020

1 reference

Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature

31 March 2020

1 reference

A gene expression database for the molecular pharmacology of cancer

31 March 2020

1 reference

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

31 March 2020

1 reference

Epistasis and balanced polymorphism influencing complex trait variation

31 March 2020

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

31 March 2020

1 reference

Strategies for optimizing combinations of molecularly targeted anticancer agents

31 March 2020

1 reference

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

31 March 2020

1 reference

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2155

1 reference

18 December 2017

Dimensions Publication ID

1011985678

0 references

1 reference

18 December 2017